Gene-modified immune cells for brain tumor that has returned
Part of Cancer clinical trials.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to attack brain tumor cells and also blocks a protein (PD-L1) that helps the tumor hide from your immune system. It is for people with a recurrent malignant glioma, a serious brain tumor that has returned despite prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of brain tumor called a malignant glioma that has come back after treatment.
- You are at least 18 years old.
- You are able to take care of yourself (ECOG score 0–2) and are expected to live more than 3 months.
- You have not had immunotherapy (like checkpoint inhibitors) before.
- You do not have severe immune system problems or autoimmune diseases, and your major organs (heart, liver, kidneys) are working well.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
This trial tests an experimental immune cell therapy for a type of brain tumor called malignant meningioma that has come back after standard treatment. The goal is to see if these special immune cells can help control the tumor.
Hear when a new Recurrent Malignant Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.